3-(2-Methanesulfonyloxyethyl)-3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenyl)acetylpyrrolidine | 167263-24-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-(2-Methanesulfonyloxyethyl)-3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenyl)acetylpyrrolidine
• 英文别名: 2-[3-(3,4-Dichlorophenyl)-1-[2-(3-propan-2-yloxyphenyl)acetyl]pyrrolidin-3-yl]ethyl methanesulfonate
• CAS: 167263-24-3
• 化学式: C₂₄H₂₉Cl₂NO₅S
• 分子量: 514.47
• InChiKey: OEIRVGNUACKTEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  81.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-苯基哌啶-4-甲酰胺单盐酸盐 、 3-(2-Methanesulfonyloxyethyl)-3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenyl)acetylpyrrolidine 生成 1-(2-{3-(3,4-Dichloro-phenyl)-1-[2-(3-isopropoxy-phenyl)-acetyl]-pyrrolidin-3-yl}-ethyl)-4-phenyl-piperidine-4-carboxylic acid amide
  参考文献：
  名称：

  Identification and chemical synthesis of MDL 105,212, a non-peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors

  摘要：

  We have synthesized and identified MDL 105,212, a non-peptide tachykinin receptor antagonist that has high affinity for human NK1 (IC50=3.11 nM) and NK2 (IC50=8.40 nM) receptors. The chemical synthesis of MDL 105,212 and the SAR of a series of racemic amide analogs are described. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00148-5
• 作为产物：
  描述：

  2-(3-(3,4-二氯苯基)吡咯烷-3-基)乙醇 生成 3-(2-Methanesulfonyloxyethyl)-3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenyl)acetylpyrrolidine
  参考文献：
  名称：

  Identification and chemical synthesis of MDL 105,212, a non-peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors

  摘要：

  We have synthesized and identified MDL 105,212, a non-peptide tachykinin receptor antagonist that has high affinity for human NK1 (IC50=3.11 nM) and NK2 (IC50=8.40 nM) receptors. The chemical synthesis of MDL 105,212 and the SAR of a series of racemic amide analogs are described. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00148-5

文献信息

• Heterocyclic tachykinin receptor antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0714891A1

  公开（公告）日：1996-06-05

  This invention provides a novel series substituted piperidines, pyrrolidines, and hexamethyleneimines which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds. The compounds have the formula wherein:    p is 1, 2, or 3;    m and n are independently 0-6;    X is         N-Ra, or CH-NRbRc,    where Ra, Rb, and Rc are independently selected from the group consisting of hydrogen and C1-C6 alkyl;    R1 and R2 are independently hydrogen, halo, trifluoromethyl, trichloromethyl, C1-C6 alkyl, or C1-C6 alkoxy; and    R3, R4, and R5 are independently selected from the group consisting of hydrogen, halo, trifluoromethyl, C1-C6 alkyl, C1-C6 alkoxy, cyano, hydroxy, amino, -NHCONH2, nitro, -CONH2, C2-C10 alkenyl, C2-C10 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C3-C8 cycloalkoxy, C1-C10 alkylthio, C1-C10 alkylamino, C2-C6 alkanoyl, and C2-C6 alkanoyloxy; or a pharmaceutically acceptable salt or solvate thereof.

  本发明提供了一系列新型的取代哌啶、吡咯烷和六亚甲基亚胺，它们可用于治疗或预防与速激肽过量有关的生理紊乱。本发明还提供了治疗此类生理紊乱的方法以及采用这些新型化合物的药物制剂。这些化合物的化学式为 其中 p 是 1、2 或 3； m 和 n 独立地为 0-6 X 是 N-Ra，或 CH-NRbRc、 其中 Ra、Rb 和 Rc 独立地选自氢和 C1-C6 烷基组成的组； R1 和 R2 独立地为氢、卤代、三氟甲基、三氯甲基、C1-C6 烷基或 C1-C6 烷氧基；以及 R3、R4 和 R5 独立选自由氢、卤素、三氟甲基、C1-C6 烷基、C1-C6 烷氧基、氰基、羟基、氨基、-NHCONH2、硝基、-CONH2、C2-C10 烯基、C2-C10 炔基、C3-C8 环烷基、C3-C8 环烯基、C3-C8 环烷氧基、C1-C10 烷硫基、C1-C10 烷基氨基、C2-C6 烷酰基和 C2-C6 烷酰氧基组成的组； 或其药学上可接受的盐或溶液。
• US5554763A
  申请人：——

  公开号：US5554763A

  公开（公告）日：1996-09-10
• US5583134A
  申请人：——

  公开号：US5583134A

  公开（公告）日：1996-12-10
• US5607947A
  申请人：——

  公开号：US5607947A

  公开（公告）日：1997-03-04
• US5679693A
  申请人：——

  公开号：US5679693A

  公开（公告）日：1997-10-21